Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment

PURPOSE: Enzalutamide resistance could result from raised androgens and be overcome by combination with abiraterone acetate. PLATO (ClinicalTrials.gov identifier: NCT01995513) interrogated this hypothesis using a randomized, double-blind, placebo-controlled design. PATIENTS AND METHODS: In period on...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Clin Oncol
Main Authors: Attard, Gerhardt, Borre, Michael, Gurney, Howard, Loriot, Yohann, Andresen-Daniil, Corina, Kalleda, Ranjith, Pham, Trinh, Taplin, Mary-Ellen
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2018
Teme:
ORIGINAL REPORTS
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6118405/
https://ncbi.nlm.nih.gov/pubmed/30028657
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2018.77.9827
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki